Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Pacira BioSciences has received a consensus rating of "Moderate Buy" from analysts, with two hold ratings and four buy ratings among six rating firms.
• The company's stock opened at $25.65, with an average 12-month target price of $33.40 set by analysts.
• Recently, Director Marcelo Bigal sold 4,912 shares at an average price of $23.67, reducing his ownership by 30.13%.

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $33.40.

A number of research analysts have recently commented on the company. Zacks Research upgraded Pacira BioSciences from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. Wall Street Zen raised Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Truist Financial raised Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price target for the company in a report on Friday, July 25th.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $25.65 on Friday. The stock's 50-day moving average is $24.91 and its two-hundred day moving average is $24.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.91. Pacira BioSciences has a 1-year low of $13.89 and a 1-year high of $27.64. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -9.23 and a beta of 0.42.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.01. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The business had revenue of $181.10 million for the quarter, compared to the consensus estimate of $183.11 million. During the same quarter in the prior year, the business posted $0.96 EPS. The business's revenue for the quarter was up 1.7% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. Analysts forecast that Pacira BioSciences will post 2.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Marcelo Bigal sold 4,912 shares of Pacira BioSciences stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the completion of the sale, the director owned 11,393 shares of the company's stock, valued at $269,672.31. The trade was a 30.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. grew its stake in shares of Pacira BioSciences by 17.8% in the second quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company's stock valued at $84,000 after buying an additional 531 shares in the last quarter. US Bancorp DE grew its holdings in shares of Pacira BioSciences by 31.0% during the first quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after purchasing an additional 537 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Pacira BioSciences by 3.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock worth $491,000 after buying an additional 794 shares during the period. Brooklyn Investment Group boosted its position in shares of Pacira BioSciences by 372.2% during the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock worth $56,000 after buying an additional 1,764 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Pacira BioSciences by 11.8% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,642 shares of the company's stock worth $422,000 after buying an additional 1,856 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.